<?xml version="1.0" encoding="UTF-8"?>
<p>Additional collaboration in the areas of antiviral discovery processes and clinical trial performance will enhance patientsâ€™ access to drug candidates with improved therapeutic potential and ideally reduce the amount of time required to bring these drugs to market. The abundance of publications and the rapid publication rate associated with the SARS-CoV-2 virus-related disease outbreak, as illustrated in this report, are indicative of the intense effort by research institutes and pharmaceutical industries to address both molecular mechanisms and therapeutic routes useful for treating current and future coronavirus outbreaks.</p>
